Theravance Biopharma, Inc. (TBPH)
NASDAQ · Manufacturing · Pharmaceutical preparations
$17.03$0.00 (0.00%) on the dayAs of the close; data may be delayed.
TBPH price, last 12 months
Key stats
- Previous close
- $17.03
- Open
- $17.06
- Day range
- $17.02 – $17.07
- 52-week range
- $13.08 – $21.03
- Volume
- 10M
- Avg volume (20 days)
- 1.2M
- Market cap
- $884.2M
Performance
1W0.0%
1M+0.1%
3M−1.4%
6M+14.3%
YTD−9.0%
1Y+21.0%
vs S&P 500, 1Y+4.3 pts
Technicals and fundamentals
About Theravance Biopharma, Inc.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $884.2M